the patients on active treatment received zoo mg. Taractan t.d.s., the patients in the placebo series receiving the same number of matching placebo tablets. Then all the tablets were dis continued for â€˜¿ 7 days. Following this the groups were crossed over so that the group which had had Taractan was now on placebo and vice versa. The procedure during the next 12 weeks was identical with that of the first phase.
the patients on active treatment received zoo mg. Taractan t.d.s., the patients in the placebo series receiving the same number of matching placebo tablets. Then all the tablets were dis continued for â€˜¿ 7 days. Following this the groups were crossed over so that the group which had had Taractan was now on placebo and vice versa. The procedure during the next 12 weeks was identical with that of the first phase.
At the end of the two weeks without drugs, just before the issue of the tablets, all patients were assessed on the following: withdrawal, thought disorganization, paranoid belligerence and agitated depression (Lorr ci al., 1960) . It is easy to administer, has demon strable reliability under test-retest and inter rater conditions. Some validity for the scale has also been assessed.
(a) Psychotic Reaction Profile

(b) Clinical Assessment Rating Scale
The psychiatrist used this scale as an aid to clinical judgment. This scale has z@ items which are grouped as follows: self.care, sociali zation, psychotic behaviour and mood. Each item is scored on a three-point scale. These points were summed at each rating. The differences between ratings were used as indicators of change in the patient's clinical state as follows: +6 or more between first and final ratings =improvement.
+2
to +5 between first and final ratings ==slight improvement.
The purpose of this trial was to evaluate the drug Taractan in the treatment of chronic schizophrenia.
Taractan (chiorprothixene) is chemically a-2-ChlorO-9-(w-dimethylaminO propylidene) thioxanthene.
It is claimed to have neuro leptic and tranquillizing properties as well as thymoleptic activity. It is also claimed to be relatively free from side-effects. This property facilitated its use in a double-blind study.
PROCEDURE
Sixty-three female chronic schizophrenics were selected; other psychotic conditions were not included. Their ages ranged from 30 to 6o years (average @ .@ years) and length of hospitalization was from 3 to 32 years (average
years).
Prior to the commencement of the trial, previous medication was discontinued for 17 days. These patients had each been receiving one or a combination of other tranquilizing drugs.
The patients were allocated at random into one of two groups so that 32 patients were in one group and 31 in the other. One group received Taractan, the other group the placebo. All the tablets were sugar-coated and identical in appearance. Every patient had her own bottle labelled with her name and â€oe¿ Taractan trial tabletsâ€•. The pharmacist held the code so that only he knew which preparation was in each bottle.
The dosage was started with one 15 mg. tablet t.d.s. and was gradually increased to a dose of two 50 mg. tablets t.d.s. over a period of 15 days. In the same way, patients on the placebo were started with three of the smaller tablets daily, the dose being increased to two of the larger tablets three times daily over the same periodof time.For a further10 weeks, (Siegel, 5956) . As each patient received placebo for three months and Taractan for three months, she acted as her own control. Each patient's initial score on Taractan was compared with her initial score on placebo, and her final score on Taractan compared with her final score on placebo. No significant differ ences were found in any of the four factors.
It was considered necessary to see if any change had taken place between first and third ratings on placebo and between first and third ratings on Taractan.
This was in case there had been a change under both placebo and Taractan. The Wilcoxon test was used again. There were no significant differences. ii. Blood urea. iii. Blood count. iv. E.S.R. (erythrocyte sedimentation rate). v. Urine.
(b) Clinical Assessment RatingScale
These procedureswere allrepeatedin the middle of the first phase and at the end of the first phase, and at the beginning, middle and end of the second phase.
During the course of the trial, at various times, i8 patients were withdrawn. Eleven patients were withdrawn because of marked mental deterioration.
This was mainly mani fested by aggressive and impulsive behaviour.
Three patients were withdrawn because of epileptiform seizures. These patientshad had a prefrontal leucotomy operationperformed some years ago. They had had fits following the operation, but none during recent years. Two of these patients were found to be receiving Taractan and one the placebo. Two patients were taken from the trial following syncopal attacks, both were on placebo tablets.
One patient died of a perforated ulcer following a long history of peptic ulcer. She was having Taractan.
Another patient was dis charged at the request of relatives. She had been receiving the placebo.
Forty-fivepatientscompleted the trial. The code was then broken to evaluate the results.
RESULTS (a) P@ychoticReaction Profile
The patients' scores on the four factors were not normally distributed.
The comparisons
T@nut I
In order to test for any differences between the treatments, some cell frequencies had to be combined to meet the requirements of the Chi Square test (Table II) In addition, at the end of the trial, before the code was broken, the nurseswere asked to judge which preparation they thought each patient was having. Their answers were correct in 33 cases out of a total of 45. This is an eventuality which would occur by chance less than 5 per cent. of the time. No side-effects were observed, which might have determined their choice, but they said that they associated improvement with Taractan and deterioration with placebo.
(d) EEG Readings
Readings of the EEG records did not reveal any abnormalities likely to be associated with either Taractan or the placebo. Grossly ab normal records were found in those cases who, it was discovered later, had had a previous history of fits. All of them were leucotomy cases.
(e) Pathological Laboratory Tests
There were no abnormal results from any of the laboratory tests carried out.
(f) Side-ejects Apart from the epileptiform seizures that occurred in those patients withdrawn from the trial therewas no evidenceof side-effects.
(g) Weight
It is the routine practice in the hospital to weigh all patients at monthly intervals. This procedure was continued in the trial. It was decided at the end to see if any changes in weight had occurred (Table  III) .
T@zi III under both preparations were significant beyond the 5 per cent. level (Guilford, 5956) .
DiscussioN
At the beginning of this trial it was hoped that should Taractan produce any change in the patients' behaviour it would be reflected by changes in the psychotic reaction profile. It has been demonstrated that Taractan produced more clinical improvement than the placebo ; however, none of the factors on the psychotic reaction profile changed. This may be because i i patients, who had become mentally deteriorated, had to be withdrawn before the final assessment of results.
It was found that the @ i patients had in fact become significantly more paranoid belligerent between their initial and final ratings. The
Wicoxon Signed Ranks Matched Pairs test for small samples yielded a difference significant beyond the 5 per cent. level. All of the @ I patients were found to be on the placebo. Had the Taractan been no more therapeutic than the placebo, roughly half of these cases would have been expected to be receiving Taractan. That all i i should be on the placebo is signifi cant beyond the i per cent. level, using the Binomial Test (Siegel, 5956) .
These I I patients, who were withdrawn from the trial, were a significantly heavier group than the patients who completed the trial. Their average weight was i i stone 5 pounds. These patients, who were on placebo, lost weight; their final average weight was i i stone 2 pounds.
It is interesting to note that whilst the patients were receiving Taractan an average gain in weight was observed, while a loss occurred when they were having the placebo. This coincides with the finding that the patients improved on Taractan. 
